← Leaderboards
Albert W Dreisbach
Tulane University Of Louisiana
$1,216,620
Attributed
$1,216,620
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $350.7K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$1,216,620 · 11
By mechanism
P20$1,050,870 · 4
M01$165,750 · 7
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- David W Busija$17,451,203
- Edward W. Inscho$12,149,427
- Jiang He$53,644,406
- Kailash N Pandey$11,062,222
- Philip J Kadowitz$3,488,699
Others in their field
Top investigators on “Genetic Polymorphism”
- Stephen S. Rich · University Of Alabama At Birmingham$76,268,916
- Richard K. Wilson · Washington University$49,172,943
- William J. Blot · Vanderbilt University$46,135,844
- Brian E Henderson · University Of Southern California$45,895,070
- David Heimbrook · Leidos Biomedical Research, Inc.$45,173,190
- Daniel H Geschwind · University Of California Los Angeles$44,299,523
Research focus
Genetic PolymorphismCytochrome P450Clinical ResearchHuman SubjectOxygenasesEpoxide HydrolaseWarfarinHypertensionChronic Renal FailureVascular EndotheliumGenotypeIsozymesEssential HypertensionEpoxidesGene MutationEnzyme ActivityEicosanoid MetabolismCytochromesCardiovascular Disorder EpidemiologyComputer Retrieval Of Information On Scientific Projects DatabaseBronchus CirculationBlood ChemistryGene ExpressionFunding
Grant awards (13)
TULANE COBRE: GENETIC POLYMORPHISMS IN EPOXYGENASE PATHWAY IN HYPERTENSION$293,119
P20 · FY2007 · RR · contact PI
TULANE COBRE: GENETIC POLYMORPHISMS IN EPOXYGENASE PATHWAY IN HYPERTENSION$281,567
P20 · FY2006 · RR · contact PI
EFFECT OF GENETIC POLYMORPHISMS IN THE EPOXYGENASE PATHWAY ON SALT EXCRETION$45,267
M01 · FY2006 · RR · contact PI
THE ROLE OF GENETIC POLYMORPHISMS IN THE EPOXYGENASE PATHWAY IN HYPERTENSION$23,508
M01 · FY2006 · RR · contact PI
THE EFFECT OF CYTOCHROME P450 CYP2C9 GENOTYPE AND PHENOTYPE ON EICOSANOID METAB$385
M01 · FY2006 · RR · contact PI
TULANE COBRE: GENETIC POLYMORPHISMS IN EPOXYGENASE PATHWAY IN HYPERTENSION$238,991
P20 · FY2005 · RR
THE ROLE OF GENETIC POLYMORPHISMS IN THE EPOXYGENASE PATHWAY IN HYPERTENSION$38,160
M01 · FY2005 · RR
EFFECT OF GENETIC POLYMORPHISMS IN THE EPOXYGENASE PATHWAY ON SALT EXCRETION$4,141
M01 · FY2005 · RR
THE EFFECT OF ENDSTAGE KIDNEY FAILURE ON THE POLYMORPHIC METABOLISM OF WARFARIN$740
M01 · FY2005 · RR
GENETIC POLYMORPHISMS IN EPOXYGENASE PATHWAY IN HYPERTENSION$237,193
P20 · FY2004 · RR
Genetic Polymorphisms in the Epoxygenase Pathway$50,014
M01 · FY2004 · RR
Effect of Endstage Kidney Disease on the CYP Phenotype$3,535
M01 · FY2004 · RR
GENETIC POLYMORPHISMS IN THE EPOXYGENASE PATHWAY IN HYPERTENSION$0
P20 · FY2002 · RR